Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened
…, L Martinez-Alsina, N Patel, K Pelletier… - ACS medicinal …, 2012 - ACS Publications
Inhibitors of the Hedgehog signaling pathway have generated a great deal of interest in the
oncology area due to the mounting evidence of their potential to provide promising …
oncology area due to the mounting evidence of their potential to provide promising …
[HTML][HTML] A phase I study to evaluate the pharmacokinetics and safety of lorlatinib in adults with mild, moderate, and severe renal impairment
S Lin, J Gong, GC Canas, P Winkle, K Pelletier… - European Journal of …, 2022 - Springer
Background and Objectives Lorlatinib is approved (100 mg once daily [QD]) for the treatment
of patients with anaplastic lymphoma kinase- (ALK) positive metastatic non-small cell lung …
of patients with anaplastic lymphoma kinase- (ALK) positive metastatic non-small cell lung …
Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21–antibody Protein conjugate
C Giragossian, C Vage, J Li, K Pelletier… - Drug Metabolism and …, 2015 - ASPET
PF-05231023, a long-acting fibroblast growth factor 21 (FGF21) analog, was generated by
covalently conjugating two engineered [des-His1, Ala129Cys]FGF21 molecules to a …
covalently conjugating two engineered [des-His1, Ala129Cys]FGF21 molecules to a …
Feasibility of singlet analysis for ligand binding assays: a retrospective examination of data generated using the Gyrolab platform
…, EA Dreher, LA Tylaska, JAA Wentland, KB Pelletier… - The AAPS Journal, 2016 - Springer
There are many sources of analytical variability in ligand binding assays (LBA). One
strategy to reduce variability has been duplicate analyses. With recent advances in LBA …
strategy to reduce variability has been duplicate analyses. With recent advances in LBA …
Bioequivalence of ertugliflozin/sitagliptin fixed‐dose combination tablets and coadministration of respective strengths of individual components
…, K Matschke, Y Liang, KB Pelletier… - Clinical …, 2019 - Wiley Online Library
A fixed‐dose combination (FDC) tablet of ertugliflozin, a selective inhibitor of sodium‐glucose
cotransporter 2, and sitagliptin, a dipeptidyl peptidase‐4 inhibitor, was developed for the …
cotransporter 2, and sitagliptin, a dipeptidyl peptidase‐4 inhibitor, was developed for the …
Safety, Tolerability, and Pharmacokinetics of PF‐06823859, an Anti–Interferon β Monoclonal Antibody: A Randomized, Phase I, Single‐and Multiple‐Ascending‐Dose …
…, M Salganik, G Berman, K Pelletier… - Clinical …, 2021 - Wiley Online Library
This double‐blind, randomized, placebo‐controlled, dose‐ascending, first‐in‐human study (NCT02766621)
assessed the safety, tolerability, and pharmacokinetics (PK) of PF‐…
assessed the safety, tolerability, and pharmacokinetics (PK) of PF‐…
Population pharmacokinetics of Inotuzumab Ozogamicin (InO) as single agent in pediatric relapsed/refractory acute lymphoblastic leukemia-results from the ITCC-059 …
E Pennesi, E Brivio, KB Pelletier, Y Chen… - Blood, 2022 - ashpublications.org
INTRODUCTION: This population pharmacokinetics (PopPK) analysis assessed the
disposition of InO, a CD22 directed antibody conjugated with calicheamicin, as single agent in …
disposition of InO, a CD22 directed antibody conjugated with calicheamicin, as single agent in …
Bioequivalence of ertugliflozin/metformin fixed‐dose combination tablets and coadministration of respective strengths of individual components
VK Dawra, Y Liang, H Wei, K Pelletier… - Clinical …, 2020 - Wiley Online Library
A fixed‐dose combination (FDC) of ertugliflozin, a selective sodium‐glucose cotransporter 2
inhibitor, and immediate‐release metformin is approved for the treatment of type 2 diabetes …
inhibitor, and immediate‐release metformin is approved for the treatment of type 2 diabetes …
Identification and characterization of PF-03814735, an oral aurora inhibitor for cancer therapy
…, J Hardink, M Luzzio, K Nelson, G Pan, K Pelletier… - Cancer Research, 2008 - AACR
5647 The Aurora kinases, a family of highly related serine/threonine kinases are key regulators
of mitosis. Aurora1 and Aurora2 (also known as AuroraB and AuroraA, respectively) play …
of mitosis. Aurora1 and Aurora2 (also known as AuroraB and AuroraA, respectively) play …
Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed‐Dose Combination Tablets to Canadian‐Sourced Metformin Coadministered With Ertugliflozin Under …
VK Dawra, K Pelletier, K Matschke… - Clinical …, 2021 - Wiley Online Library
A fixed‐dose combination (FDC) product of a selective sodium‐glucose cotransporter 2
inhibitor ertugliflozin and immediate‐release metformin is approved for type 2 diabetes mellitus …
inhibitor ertugliflozin and immediate‐release metformin is approved for type 2 diabetes mellitus …